Ventyx Biosciences to be Acquired by Eli Lilly for $1.2 Billion in All-Cash Deal

summarizeSummary

Ventyx Biosciences announced its acquisition by Eli Lilly for $1.2 billion in an all-cash transaction, providing shareholders with a significant premium and certain value.

check_boxKey Events

• Acquisition Agreement

  Eli Lilly will acquire all outstanding shares of Ventyx Biosciences for $14.00 per share in an all-cash transaction, totaling approximately $1.2 billion in aggregate equity value.

• Significant Premium

  The purchase price represents a substantial premium of approximately 62% over Ventyx's 30-day volume-weighted average price (VWAP) as of January 5, 2026.

• Board Approval & Shareholder Support

  Ventyx's Board of Directors unanimously approved the merger. Key shareholders, including directors and officers representing about 10% of outstanding stock, have signed voting agreements in favor of the transaction.

• Expected Closing

  The transaction is anticipated to close in the first half of 2026, subject to customary closing conditions, including regulatory and Ventyx stockholder approvals.

auto_awesomeAnalysis

This definitive agreement for Eli Lilly to acquire Ventyx Biosciences represents a highly significant and positive outcome for Ventyx shareholders. The all-cash transaction offers a substantial premium and provides immediate, certain value. The acquisition is expected to accelerate the development of Ventyx's pipeline by leveraging Eli Lilly's industry-leading resources and infrastructure. The unanimous board approval and voting agreements from key shareholders, including directors and officers, indicate strong internal support and a high likelihood of the transaction's completion.